Bioxydyn delivers quantitative brain MRS biomarkers with particular expertise in hypoxic-ischaemic encephalopathy (HIE).

We design and implement robust in vivo spectroscopy protocols, enabling reliable measurement of cerebral metabolites and treatment response. Our experience includes cross-site harmonisation, quality-controlled spectral analysis, and validated quantification pipelines. Through dedicated phantom validation and controlled processing workflows, we ensure spectroscopy biomarkers are reproducible, accurate, and suitable for pharmaceutical-grade studies.